Titan has a broad intellectual property portfolio, with issued patents and patent applications covering formulations, processes and methods related to the ProNeura® technology platform for the treatment of certain chronic diseases, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. These include implantable products in development for the prevention of opioid relapse following detoxification from opioids, and for the treatment of moderate-to-severe chronic pruritus.
Titan owns a granted patent family for the ProNeura technology platform for continuous drug delivery following subdermal placement, which is broadly applicable to the treatment of several chronic indications. These patents are issued in the United States, Europe, Japan, South Korea, Singapore, Hong Kong, India, Canada, Mexico, Australia, and South Africa, and will expire in 2031. Additional patent families are pending which cover further aspects and embodiments of the ProNeura system.
Titan also owns United States and Canadian patents covering methods of using Probuphine® (buprenorphine) implant, a ProNeura-based buprenorphine-releasing implant for the treatment of opioid addiction, which expire in 2024 and 2023 respectively. Additionally, Titan is the owner of patents covering ProNeura implants for administering dopamine agonists. These patents are issued in the United States, Europe, Japan, China, South Korea, Hong Kong, Israel, Canada, Mexico, Australia, New Zealand, and South Africa, and expire in 2024.